Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IN-VIVO CANCER GENE-THERAPY WITH A RECOMBINANT INTERLEUKIN-2 ADENOVIRUS VECTOR
Autore:
TOLOZA EM; HUNT K; SWISHER S; MCBRIDE W; LAU R; PANG S; RHOADES K; DRAKE T; BELLDEGRUN A; GLASPY J; ECONOMOU JS;
Indirizzi:
UNIV CALIF LOS ANGELES,SCH MED,DIV SURG ONCOL,10833 LE CONTE AVE,RM 54-140 CHS LOS ANGELES CA 90095 UNIV CALIF LOS ANGELES,SCH MED,DIV SURG ONCOL LOS ANGELES CA 90095 UNIV CALIF LOS ANGELES,SCH MED,DIV RADIAT ONCOL LOS ANGELES CA 90095 UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL LOS ANGELES CA 90024 UNIV CALIF LOS ANGELES,SCH MED,DIV UROL LOS ANGELES CA 90024 UNIV CALIF LOS ANGELES,SCH MED,DIV PATHOL & LAB MED LOS ANGELES CA 00000
Titolo Testata:
Cancer gene therapy
fascicolo: 1, volume: 3, anno: 1996,
pagine: 11 - 17
SICI:
0929-1903(1996)3:1<11:ICGWAR>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-INFILTRATING LYMPHOCYTES; HUMAN-MELANOMA CELLS; ANTITUMOR RESPONSE; INHIBITION; EXPRESSION; IMMUNITY; LINES;
Keywords:
ADENOVIRUS; INTERLEUKIN-2; FIBROSARCOMA; CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
45
Recensione:
Indirizzi per estratti:
Citazione:
E.M. Toloza et al., "IN-VIVO CANCER GENE-THERAPY WITH A RECOMBINANT INTERLEUKIN-2 ADENOVIRUS VECTOR", Cancer gene therapy, 3(1), 1996, pp. 11-17

Abstract

Recombinant adenovirus (AdV) vectors are highly efficient at in vitroand in vivo gene delivery. In vivo therapy of established murine fibrosarcoma and mammary carcinomas was attempted with intratumoral injections of a recombinant AdV vector in which the human interleukin-2 (IL-2) gene was driven by the cytomegalovirus enhancer/promoter. Delayed growth and rejection of some tumors could be achieved with a cumulativevirus dose of 2 to 6 X 10(9) plaque-forming units in two or three divided doses. Lower viral doses were ineffective, and higher doses resulted in animal death due to IL-2 toxicity. Using AdV vectors with the marker genes beta-galactosidase and luciferase, it is clear that even small volume (10 to 20 mu L) intratumoral injections result in substantial systemic delivery of a portion of the virus dose. These findings define the potential and limitations of in vivo AdV-based cancer gene therapy and provide supper? for strategies to develop tumor-specific vectors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 20:35:31